1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone

Long-Time Partners Decide Fate Of Two Drugs

 
• By Mandy Jackson

Development has ended for BIIB105 in ALS after it failed to clear a crucial biomarker and show clinical benefit. Also, Biogen opted not to advance ION582 for Angelman syndrome, so Ionis will go it alone.

Illustration of abstract neuron on a blue background
Ionis will bolster its in-house neurology portfolio with wholly-owned ION582 • Source: Shutterstock

Long-time collaborators Biogen, Inc. and Ionis Pharmaceuticals, Inc. announced updates for two programs in mid-stage clinical development on 16 May, reporting that they will end development of BIIB105 after the drug failed in a Phase I/II clinical trial in amyotrophic lateral sclerosis (ALS). Ionis also revealed updated results from a Phase I/IIa trial of ION582 (BIIB121) in Angelman syndrome and said it will take the drug into Phase III on its own after Biogen opted out of the program.

Key Takeaways

  • Biogen and Ionis will discontinue development of BIIB105 for ALS after the drug failed to provide clinical benefit in a Phase I/II study.

Both companies traded lower on the updates, with Biogen closing down 2.2% at $230.04 per share and Ionis ending the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.